By Brooks M. Deering, The Chicago Times
September 29, 2022
NEW YORK — Merck & Co announced on Wednesday that it will allow China based Sinopharm to distribute and import Merck’s COVID-19 antiviral drug molnupiravir in China, pending approval by the Chinese government.
In a statement, Merck said it reached a cooperation framework agreement that grants Sinopharm distribution and exclusive import rights of the medicine on the Chinese mainland. In addition, Merck agreed to allow Sinopharm’s affiliate, China National Biotec Group, to manufacture the drug under a transfer technology agreement.